98.02
+2.96%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RemeGen Co
Its shares trade on Shanghai under the ticker 688331.SS. It has been listed since 9 November 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.25bn and net income of CN¥708.5m. At that date it held total assets of CN¥7.25bn and shareholders' equity of CN¥2.32bn.
RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The firm is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The firm's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Nov 2020
- Employees
- 3,332
- Website
- remegen.cn ↗
Leadership
Pay as last reported
- Mr. Weidong WangExecutive Chairman of the Board, since 2013CN¥2.5m
- Mr. Jianmin FangChief Executive Officer, Chief Scientific Officer, General Manager, Executive Director, since 2008CN¥7.4m
- Mr. Shaojing TongChief Financial Officer, Joint Company SecretaryCN¥4.3m
- Mr. Qingkai WenExecutive Director, Secretary of the Board, since 2020CN¥2.3m
- Mr. Jian LinExecutive Director, since 2008CN¥809,400
- Ms. Xiaodi SuNon-Executive Director
- Mr. Liqiang WangNon-Executive Director
- Mr. Yunjin ChenIndependent DirectorCN¥300,000
- Mr. Xianjing HaoIndependent DirectorCN¥300,000
- Mr. Guobin HuangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 62
- Social
- 65
- Governance
- 79
- Direct emissions (scope 1)
- 54.15 t
- Energy emissions (scope 2)
- 59,099.23 t
- Women in the workforce
- 54.01137%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in the biotechnology sector with a focus on innovative biopharmaceuticals.
- Headquartered in Yantai, China, with 3,332 employees.
- Main products include therapeutic antibody drugs such as ADCs and bispecific antibodies.
Weaknesses
- Primarily conducts business in the domestic market only.
- No mention of international market presence or global expansion strategies.
- Limited product portfolio details beyond the main products listed.
Opportunities
- Growing demand for innovative biopharmaceuticals in China.
- Potential for expanding into international markets beyond domestic operations.
- Increasing focus on therapeutic antibody drugs for major diseases like oncology.
Threats
- Dependence on domestic market may limit growth opportunities.
- Competition in the biotechnology sector could intensify.
- Regulatory challenges in the biopharmaceutical industry may affect operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.